News Release Detail
July 18, 2006
Mylan Chosen To Testify Before Congress Concerning Authorized Generics, Citizen Petitions, Declaratory Judgments And Issues Concerning The Delay Of Generic Pharmaceutical Approvals
Mylan Chosen To Testify Before Congress Concerning Authorized Generics, Citizen Petitions, Declaratory Judgments And Issues Concerning The Delay Of Generic Pharmaceutical Approvals
What: Mylan Laboratories Inc. (NYSE: MYL) has accepted an invitation to
testify before the U.S. Senate Special Committee on Aging during
its hearing titled "The Generic Drug Maze: Speeding Access to
Affordable, Life Saving Drugs."
Mylan was invited by Sen. Gordon Smith, Ore., chairman of the
committee, and Sen. Herb Kohl, Wis., ranking member of the
committee.
Heather Bresch, Mylan's senior vice president of strategic
corporate development in the Office of the CEO, will testify on
behalf of Mylan. As part of Mylan's testimony, Ms. Bresch will
address impediments that unfairly delay or hinder consumer access
to affordable generic pharmaceuticals including authorized
generics during the 180-day exclusivity period, citizen petitions
and declaratory judgments.
Other members of the committee include Sens. Richard Shelby, Ind.,
Susan Collins, Maine, James Talent, Mo., Elizabeth Dole, N.C., Mel
Martinez, Fla., Larry Craig, Idaho, Rick Santorum, Pa., Conrad
Burns, Mont., Lamar Alexander, Tenn., Jim DeMint, S.C., James
Jeffords, Vt., Ron Wyden, Ore., Blanche Lincoln, Ark., Evan Bayh,
Ind., Thomas Carper, Del., Bill Nelson, Fla., Hillary Rodham
Clinton, N.Y., and Ken Salazar, Colo.
testify before the U.S. Senate Special Committee on Aging during
its hearing titled "The Generic Drug Maze: Speeding Access to
Affordable, Life Saving Drugs."
Mylan was invited by Sen. Gordon Smith, Ore., chairman of the
committee, and Sen. Herb Kohl, Wis., ranking member of the
committee.
Heather Bresch, Mylan's senior vice president of strategic
corporate development in the Office of the CEO, will testify on
behalf of Mylan. As part of Mylan's testimony, Ms. Bresch will
address impediments that unfairly delay or hinder consumer access
to affordable generic pharmaceuticals including authorized
generics during the 180-day exclusivity period, citizen petitions
and declaratory judgments.
Other members of the committee include Sens. Richard Shelby, Ind.,
Susan Collins, Maine, James Talent, Mo., Elizabeth Dole, N.C., Mel
Martinez, Fla., Larry Craig, Idaho, Rick Santorum, Pa., Conrad
Burns, Mont., Lamar Alexander, Tenn., Jim DeMint, S.C., James
Jeffords, Vt., Ron Wyden, Ore., Blanche Lincoln, Ark., Evan Bayh,
Ind., Thomas Carper, Del., Bill Nelson, Fla., Hillary Rodham
Clinton, N.Y., and Ken Salazar, Colo.
When: Thursday, July 20, 2006 at 10 a.m.
Where: Dirksen Senate Office Building, Washington, D.C., Room 106
Contacts:
Mylan: Patrick Fitzgerald
724-514-1811
Patrick.Fitzgerald@mylanlabs.com
Senator Kohl: Joe Bonfiglio
202-224-2534
SOURCE Mylan Laboratories Inc.
07/18/2006 P
PRNewswire-FirstCall -- July 18
Web site: http://www.mylan.com
(MYL)